*Institute Ramón y Cajal for Health Research (IRYCIS)
†CIBER-ONC, Carlos III Health Institute
§Department of Pathology, Ramón y Cajal University Hospital
¶¶Faculty of Medicine, University of Alcalá de Henares, Madrid
‡Clinical Area of Gynecological Oncology
¶Laboratory of Molecular Biology, Valencian Institute of Oncology
∥∥Oncogynecologic Department, Initia Oncology, Hospital Quironsalud Valencia, Valencia
∥Department of Medical Oncology, Hospital Santa Creu i Sant Pau
§§Department of Pathology, Germans Trias i Pujol University Hospital, Barcelona
#Department of Hematology and Hemotherapy, Navarra University Clinic, Pamplona
**Department of Pathology, Elche University Hospital, Elche
††Department of Pathology, Marqués de Valdecilla University Hospital, Santander
‡‡Department of Pathology, Santa Lucia University Hospital, Murcia, Spain
J.A.L-G., A.P., and J.P. contributed equally as corresponding authors.
S.L. and I.R. contributed equally as first authors.
Conflicts of Interest and Source of Funding: Supported by grants from the Carlos III Health Institute (ISCIII) (PIE15/00050 and PI16/00887) and CIBERONC (CB16/12/00316), cofinanced by the European Development Regional Fund “A way to achieve Europe” (FEDER), and by the Spanish Association Against Cancer Scientific Foundation (aecc) (Grupos Coordinados Traslacionales aecc 2018 and AIO-aecc 2016). This study has also been partially funded by the Spanish Group of Research in Ovarian Cancer (GEICO group). The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.
Correspondence: José Palacios, MD, PhD, Hospital Ramón y Cajal, Carr. de Colmenar Viejo, Madrid 28034, Spain (e-mail: [email protected]).
